LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 1 | K08 | 72 | hr | 1476 | 1395 | 3694 | 0.3776 | -0.0369 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 2 | K08 | 72 | hr | 1476 | 1717 | 3694 | 0.4648 | 0.1084 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 3 | K08 | 72 | hr | 1476 | 1485 | 3694 | 0.4020 | 0.0037 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 1 | J02 | 72 | hr | 1476 | 2873 | 3694 | 0.7777 | 0.6297 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 2 | J02 | 72 | hr | 1476 | 3046 | 3694 | 0.8246 | 0.7077 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 3 | J02 | 72 | hr | 1476 | 2818 | 3694 | 0.7629 | 0.6049 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 1476 | 3300 | 3694 | 0.8933 | 0.8223 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 1476 | 3381 | 3694 | 0.9153 | 0.8588 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 1476 | 3636 | 3694 | 0.9843 | 0.9738 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 1 | G08 | 72 | hr | 1476 | 4575 | 3694 | 1.2385 | 1.3973 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 2 | G08 | 72 | hr | 1476 | 4176 | 3694 | 1.1305 | 1.2174 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 3 | G08 | 72 | hr | 1476 | 4272 | 3694 | 1.1565 | 1.2607 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 1 | D08 | 72 | hr | 1476 | 3055 | 3694 | 0.8270 | 0.7118 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 2 | D08 | 72 | hr | 1476 | 3013 | 3694 | 0.8156 | 0.6929 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 3 | D08 | 72 | hr | 1476 | 3029 | 3694 | 0.8200 | 0.7001 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 1 | M08 | 72 | hr | 1476 | 3516 | 3694 | 0.9518 | 0.9197 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 2 | M08 | 72 | hr | 1476 | 3859 | 3694 | 1.0447 | 1.0744 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 3 | M08 | 72 | hr | 1476 | 3606 | 3694 | 0.9762 | 0.9603 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 1 | L14 | 72 | hr | 1476 | 1549 | 3694 | 0.4193 | 0.0326 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 2 | L14 | 72 | hr | 1476 | 2548 | 3694 | 0.6898 | 0.4831 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 3 | L14 | 72 | hr | 1476 | 2306 | 3694 | 0.6243 | 0.3740 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1476 | 3358 | 3694 | 0.9090 | 0.8484 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1476 | 3517 | 3694 | 0.9521 | 0.9202 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1476 | 3639 | 3694 | 0.9851 | 0.9752 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 1 | J08 | 72 | hr | 1476 | 3434 | 3694 | 0.9296 | 0.8827 |